Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878638 | 1.00 | PPARD (0.69) | PPARDFFAR1KDM4CPPARAPPARG | |
| SCHEMBL2883493 | 1.00 | PPARD (0.69) | PPARDFFAR1KDM4CPPARAPPARG | |
| SCHEMBL2995086 | 0.92 | PPARD (0.80) | PPARDPPARAPPARG | |
| SCHEMBL821101 | 0.92 | PPARD (0.80) | PPARDPPARAPPARG | |
| SCHEMBL820621 | 0.92 | PPARD (0.80) | PPARDPPARAPPARG | |
| SCHEMBL8884747 | 0.89 | MTNR1A (0.61) | PPARD | |
| SCHEMBL14378591 | 0.88 | PPARD (0.67) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL4622325 | 0.87 | SIGMAR1 (0.56) | PPARDKDM4C | |
| SCHEMBL4758807 | 0.87 | PPARD (0.59) | PPARDFFAR1KDM4CPPARAPPARG | |
| SCHEMBL4758808 | 0.87 | PPARD (0.59) | PPARDFFAR1KDM4CPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-0971878-B1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1846379-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7256204-B2 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-14 | — | — | US | disclosed |
| WO-2006083781-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20040077867-A1 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-0971878-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998038156-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | PPARD 679/4885FFAR1 1152/4885KDM4C 3172/4885 |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | PPARD 3635/4885FFAR1 1181/4885KDM4C 3503/4885 |
| US-20040077867-A1 | Amine compounds, their production and use | QSOX1, APP, NPR1 | PPARD 3746/4885FFAR1 1024/4885KDM4C 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.